Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open …
A Bauer, M Schreinlechner, N Sappler… - The Lancet …, 2021 - thelancet.com
Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme
2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed …
2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed …
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open …
A Bauer, M Schreinlechner, N Sappler… - The Lancet …, 2021 - europepmc.org
Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme
2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed …
2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed …
[HTML][HTML] Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled …
A Bauer, M Schreinlechner, N Sappler… - The Lancet …, 2021 - ncbi.nlm.nih.gov
Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme
2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed …
2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed …
[引用][C] Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled …
A Bauer, W von Scheidt - 2021 - opus.bibliothek.uni-augsburg.de
OPUS 4 | Discontinuation versus continuation of renin-angiotensin-system inhibitors in
COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label …
COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label …
[引用][C] Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled …
A Bauer, M Schreinlechner, N Sappler… - The Lancet Respiratory …, 2021 - cir.nii.ac.jp
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID):
a prospective, parallel group, randomised, controlled, open-label trial | CiNii Research CiNii …
a prospective, parallel group, randomised, controlled, open-label trial | CiNii Research CiNii …
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open …
A Bauer, M Schreinlechner… - The Lancet …, 2021 - epub.ub.uni-muenchen.de
BACKGROUND SARS-CoV-2 entry in human cells depends on angiotensin-converting
enzyme 2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS) …
enzyme 2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS) …
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open …
A Bauer, M Schreinlechner, N Sappler, T Dolejsi, H Tilg… - 2021 - pubmed.ncbi.nlm.nih.gov
Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme
2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed …
2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed …
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open …
A Bauer, M Schreinlechner, N Sappler, T Dolejsi… - The Lancet Respiratory …, 2021 - Elsevier
Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme
2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed …
2, which can be upregulated by inhibitors of the renin–angiotensin system (RAS). We aimed …
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open …
A Bauer, M Schreinlechner… - Lancet …, 2021 - epub.ub.uni-muenchen.de
Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme
2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed …
2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed …
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open …
A Bauer, M Schreinlechner, N Sappler… - The Lancet …, 2021 - europepmc.org
Background SARS-CoV-2 entry in human cells depends on angiotensin-converting enzyme
2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed …
2, which can be upregulated by inhibitors of the renin-angiotensin system (RAS). We aimed …